Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.

Abstract

BACKGROUND The approval of the oral direct thrombin inhibitor, dabigatran etexilate, gave patients an alternative to oral anticoagulation with warfarin. Like all anticoagulants, the primary adverse event (AE) associated with dabigatran is bleeding. Until the FDA approval of idarucizumab, there had been no reversal agent for dabigatran-induced… (More)

Topics

Cite this paper

@article{Thibault2016IdarucizumabFR, title={Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.}, author={Nathan Thibault and Amanda M Morrill and Kristine C. Willett}, journal={American journal of therapeutics}, year={2016} }